Where does Momotaro-Gene Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Momotaro-Gene Inc. ranks #32,541 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Momotaro-Gene Inc. hold?

Momotaro-Gene Inc. holds 8 US utility patents granted between 2015 and 2024, spanning 7 technology areas.

What is Momotaro-Gene Inc.'s Innovation Score?

Momotaro-Gene Inc. has an Innovation Score of 34.1 out of 100 (47th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Momotaro-Gene Inc. focus on?

Momotaro-Gene Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 7 patents, ranking #2,588 of 6,058 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

Is Momotaro-Gene Inc.'s patent grant rate increasing or decreasing?

Momotaro-Gene Inc.'s recent grant velocity is -40% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Momotaro-Gene Inc.'s patents?

Momotaro-Gene Inc.'s patents average 6.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Momotaro-Gene Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Momotaro-Gene Inc.

USPTO PatentsView assignee record - 8 granted patents across 7 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Momotaro-gene ranks #32,541 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 7 technology areas.

#32,541
of 49,997 US assignees by volume: 47th percentile
by Innovation Score (34.1/100): 6.4
avg claims per patent: -40%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R32541 · Foreign Corporation #32,541 · 8 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-SPARSE · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

GRANTS-MICRO 8 grants
MID-PACK #32,541/49,997
PHOTO-FINISH Mobile Imaging in…
CPC-NARROW A61P · 7 areas
INNOV-THIN 34.1/100
CLAIMS-SPARSE 6.4 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DOWN -40% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Mobile Imaging in Sweden AB (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Momotaro-gene’s 34.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.6 pts (22%) Velocity 13.3 pts (39%) Breadth 9.4 pts (28%) Claim depth 3.8 pts (11%)

Qualcomm Incorporated · highest

85
Momotaro-Gene · this assignee

34
3D Lighting… · lowest

7

What this shows Momotaro-gene's Innovation Score is 34.1/100 (47th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Momotaro-gene?

Each dot is one of Momotaro-gene’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Momotaro-gene’s own 6.4 claims/patent is at or below the 14.5 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Momotaro-gene vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Momotaro-gene's grants concentrate

Momotaro-Gene Inc. is a focused PatentsView assignee: 7 CPC subclasses with 87.5% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2015 (2 grants) versus a trough of 1 in 2016. By volume, Momotaro-gene sits between Mobile Imaging in Sweden AB and Muhlbauer Technology GmbH.

Momotaro-gene's three-year grant acceleration

Momotaro-Gene Inc. shows 2 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Mobile Imaging in…

8
Mobius Protection…

8
Mole-richardson

8
Molyworks Material

8
Mondelez Europe

8
Monroe Truck Equi…

8
Monsanto Invest B…

8
Muhlbauer Technol…

8
Momotaro-gene ◀

8

What this shows Momotaro-Gene holds 8 patents at rank #32,542, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Momotaro-Gene

By rank, the assignees closest to #32,542 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Momotaro-Gene's primary technology class.

Momotaro-gene's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

34 47th percentile higher than 47% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Momotaro-Gene Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	2	25.0%
2016	1	12.5%
2017	1	12.5%
2018	1	12.5%
2020	1	12.5%
2022	1	12.5%
2024	1	12.5%

Which technologies does Momotaro-Gene Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 7

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 7

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 7

C07K - Peptides 5

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 1

A01K - Animal HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; Rearing OR Breeding Animals, NOT Otherwise Provided FOR; NEW Breeds OF Animals 1

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 1

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Momotaro-Gene Inc.'s patent record in context - here's where to go next.

Momotaro-Gene Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 87.5% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #32,541 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Momotaro-Gene Inc. against Mobile Imaging in Sweden AB, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 34.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.